(Q78214499)
Statements
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study (English)
C Karanes
K J Kopecky
D R Head
M R Grever
H E Hynes
E H Kraut
R H Vial
A Lichtin
S Nand
1 September 1999